FDA rejects experimental therapy to treat rare blood cancer. The FDA's internal reviewers recommended approval of this therapy. The FDA's decision is considered mysterious. The article also covers a diet pill from Lilly. These topics are part of an overview of pharmaceutical news. Additional information includes various drug news. The FDA's decision raises questions about the process of approving therapies.